Table 1 Baseline characteristics according to treatment arm.
Arm A (Chemotherapy) | Arm B (Chemotherapy + cetuximab) | All patients | |
|---|---|---|---|
N = 72 | N = 78 | N = 150 | |
Age (median) | 59 y. | 62.5 y. | 61 y. |
Age > 65 y. | 26 (36%) | 33 (42%) | 59 (39%) |
Gender: male | 32 (44%) | 34 (44%) | 66 (44%) |
WHO PS 0 | 24 (33%) | 34 (45%) | 58 (39%) |
WHO PS 1 | 47 (65%) | 42 (55%) | 89 (60%) |
WHO PS 2 | 1 (1%) | 0 (0%) | 1 (1%) |
Leucocytes > 10 | 29 (40%) | 25 (32%) | 54 (36%) |
LDH > ULN | 46 (64%) | 53 (68%) | 99 (66%) |
Liver met. | 38 (53%) | 34 (44%) | 72 (48%) |
Lung met. | 16 (22%) | 20 (29%) | 36 (28%) |
Lymph-node met. | 37 (51%) | 41 (53%) | 78 (52%) |
Bone met. | 6 (8%) | 7 (9%) | 13 (10%) |
No. of met. sites* | |||
1 site | 16 (22%) | 11 (14%) | 27 (18%) |
2 sites | 25 (35%) | 24 (31%) | 49 (33%) |
3 sites | 17 (24%) | 26 (33%) | 43 (29%) |
4 sites | 8 (11%) | 11 (14%) | 19 (13%) |
5 sites | 4 (6%) | 3 (4%) | 7 (5%) |
6 sites | 2 (3%) | 3 (4%) | 5 (3%) |
